Overview
Rules 1.1.0 · as of 14 Sep 2026
3 forecasters · 2,967 statements · 227 admittedA statement that passed intake: sincere, the person's own claim, forward-looking, inside the five areas, and not excluded by a reason code. Only admitted statements become items. Method › · 44 resolvedA cluster with at least one scored item. Only resolved clusters count toward n. Method › events
Leaderboard
The intervals overlap; no ranking yet.
How to read
Headline panel · 3 forecasters
Forecasters
Every forecaster has a score.
| Forecaster | Coverage | Found | Admitted | Resolved | Score | Hit rate | Pending |
|---|---|---|---|---|---|---|---|
| Owen Scott Muir | Full archive (tier A) | 2,500 | 72 | 21 | 0.20 | 78% | 38 |
| Christian Angermayer | Ad hoc collection (tier C) | 197 | 48 | 10 | 0.52 | 30% | 28 |
| Rick Doblin | Ad hoc collection (tier C) | 270 | 87 | 13 | 0.36 | 36% | 12 |
How to read
Headline panel · 3 forecasters
Forecasters by area
Muir scores best in Regulatory decisions: Brier 0.19 on 11 events.
Resolved events by area
Boldness and accuracy
Muir sits 0.27 from the base rate on average, at Brier 0.20.
Headline panel
Admission
227 admitted1 in 13 statements is a checkable claim; 76 are resolved.
How to read
Every statement · all forecasters
Not admitted by reason
Vague or promotional accounts for 855 of 2,740 statements not admitted.
How to read
Not admitted · reason codes
Claims that came due
2 of the last 12 came true.
Headline panel · all forecasters · newest first
Shared events
4 events have claims from more than one forecaster.
| Event | Forecaster | Deadlines | P | State | Cluster Brier |
|---|---|---|---|---|---|
| FDA approval of midomafetamine (MDMA-assisted therapy) for PTSD | Angermayer | 31 Dec 2024 15 Apr 2025 1 Jun 2025 5 Jun 2026 20 Feb 2027 | 0.70 0.70 0.90 0.70 0.30 | 0.60 | |
| FDA approval of midomafetamine (MDMA-assisted therapy) for PTSD | Doblin | 4 Apr 2018 2 Dec 2021 31 Dec 2021 11 Jun 2022 20 Aug 2022 13 Dec 2022 31 Dec 2022 30 Jun 2023 30 Sep 2023 31 Oct 2023 31 Dec 2023 5 Jan 2024 31 May 2024 29 Jun 2024 30 Jun 2024 31 Aug 2024 31 Dec 2024 5 Jan 2025 12 Sep 2025 29 Sep 2025 9 Nov 2025 16 Aug 2026 27 Dec 2026 9 May 2027 27 Dec 2027 7 Jan 2028 | 0.90 0.90 0.61 0.90 0.50 0.70 0.70 0.50 0.70 0.70 0.69 0.90 0.70 0.70 0.70 0.70 0.63 0.50 0.50 0.70 0.50 0.70 0.90 0.90 0.70 0.90 | 0.50 | |
| FDA approval of midomafetamine (MDMA-assisted therapy) for PTSD | Muir | 7 Jun 2026 10 Jun 2026 15 Jun 2026 26 Jun 2026 11 Aug 2026 5 Sep 2027 | 0.50 0.10 0.30 0.70 0.10 0.10 | 0.17 | |
| First FDA approval of a psychedelic medicine (class) | Angermayer | 7 Aug 2025 10 May 2031 | 0.90 0.90 | 0.81 | |
| First FDA approval of a psychedelic medicine (class) | Doblin | 5 Apr 2019 | 0.90 | – | |
| First FDA approval of a psychedelic medicine (class) | Muir | 10 Jun 2026 27 Jul 2027 2 Jul 2028 25 Aug 2028 | 0.50 0.90 0.90 0.90 | 0.25 | |
| FDA approval of COMP360 (psilocybin) for major depressive disorder | Angermayer | 16 Nov 2024 4 Apr 2025 16 Nov 2025 31 Dec 2026 28 Jul 2027 7 May 2028 | 0.90 0.70 0.90 0.90 0.90 0.70 | 0.70 | |
| FDA approval of COMP360 (psilocybin) for major depressive disorder | Muir | 31 Dec 2026 | 0.90 | – | |
| Psilocybin, LSD or MDMA drug product approved with retail-pharmacy dispensing | Angermayer | 20 Sep 2026 | 0.20 | – | |
| Psilocybin, LSD or MDMA drug product approved with retail-pharmacy dispensing | Muir | 16 Aug 2028 19 Aug 2028 27 Aug 2028 | 0.10 0.10 0.10 | – |
How to read
Registry
AreasRegulatory decisions · Trial outcomes · Company and market outcomes · Payer and policy · Practice adoption